A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
Georgina V Long, Reinhard Dummer, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert HI Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J Olszanski, Thomas F Gajewski, John M Kirkwood, Olga Kuznetsova, Lisa Chen, David R Kaufman, Jeffrey Chou, F Stephen Hodi
Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P181; DOI: 10.1186/2051-1426-3-S2-P181
